A Novel MYH9-RET Fusion Occurrence and EGFR T790M Loss as an Acquired Resistance Mechanism to Osimertinib in a Patient with Lung Adenocarcinoma: A Case Report

BACKGROUND: Osimertinib is a novel and irreversible epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeting EGFR sensitive mutations and EGFR exon20 p.T790M mutation, which demonstrated superior progression-free survival (PFS) and overall survival (OS). CASE PRESENTATION: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yanwei, Pei, Lina, Luo, Ningning, Chen, Dongsheng, Meng, Lingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646409/
https://www.ncbi.nlm.nih.gov/pubmed/33173309
http://dx.doi.org/10.2147/OTT.S267524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646409/
https://www.ncbi.nlm.nih.gov/pubmed/33173309
http://dx.doi.org/10.2147/OTT.S267524

Ejemplares similares